CYTK
HEALTHCARECytokinetics Inc
$74.84-2.25 (-2.92%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CYTK Today?
No stock-specific AI insight has been generated for CYTK yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$29.31$80.20
$74.84
Fundamentals
Market Cap$9.3B
P/E Ratio—
EPS$-6.54
Dividend Yield—
Dividend / Share—
ROE-5.7%
Profit Margin—
Debt / Equity—
Trading
Volume4.8M
Avg Volume (10D)—
Shares Outstanding124.4M
CYTK News
21 articles- Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC SaysYahoo Finance·May 8, 2026
- Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 MillionYahoo Finance·May 8, 2026
- Earnings Beat: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsYahoo Finance·May 7, 2026
- Cytokinetics Announces Pricing of Upsized Public Offering of Common StockYahoo Finance·May 7, 2026
- CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo LaunchYahoo Finance·May 6, 2026
- Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC SaysYahoo Finance·May 6, 2026
- Cytokinetics, Incorporated Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Cytokinetics (CYTK) Hits 52-Week High as Revenues Soar Over 1,000%Yahoo Finance·May 6, 2026
- Cytokinetics Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM TrialMarketbeat·May 5, 2026
- Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Cytokinetics (CYTK) Q1 2026 Earnings TranscriptMotley Fool·May 5, 2026
- How This Biotech Scored 'A Clear Win' Where Bristol Myers FailedYahoo Finance·May 5, 2026
- Cytokinetics Announces Proposed Public Offering of Common StockYahoo Finance·May 5, 2026
- Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 5, 2026
- Cytokinetics stock hits 52-week high after ACACIA-HCM trialQz·May 5, 2026
- Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic CardiomyopathyYahoo Finance·May 5, 2026
- Cytokinetics heart drug scores in closely watched trialBiopharmadive·May 5, 2026
- Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026Yahoo Finance·May 4, 2026
- Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?Yahoo Finance·May 4, 2026
- Cytokinetics to Announce First Quarter Results on May 5, 2026GlobeNewswire Inc.·Apr 21, 2026
All 21 articles loaded
Price Data
Open$78.38
Previous Close$77.09
Day High$79.01
Day Low$72.15
52 Week High$80.20
52 Week Low$29.31
52-Week Range
$29.31$80.20
$74.84
Fundamentals
Market Cap$9.3B
P/E Ratio—
EPS$-6.54
Dividend Yield—
Dividend / Share—
ROE-5.7%
Profit Margin—
Debt / Equity—
Trading
Volume4.8M
Avg Volume (10D)—
Shares Outstanding124.4M
About Cytokinetics Inc
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—